Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Comparison of commonly used solid tumor targeted gene sequencing panels for estimating tumor mutation burden shows analytical and prognostic concordance within the cancer genome atlas cohort

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2020-000613Source: DataRank Database

Comparison of commonly used solid tumor targeted gene sequencing panels for estimating tumor mutation burden shows analytical and prognostic concordance within the cancer genome atlas cohort is a research paper published in Journal for ImmunoTherapy of Cancer (2020). On theSindex it has a DataRank of 0. It has been cited 40 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access40 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 2.29)OA: goldTopics (74)Linked Datasets (16)DataCite Reuse (16)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Shulei Sun,Zied Gaieb ORCID,John Thorson ORCID,Sarah S. Murray ORCID,Nicholas Bevins ORCID

Live enrichment

PubMed:32217764 PMC:PMC7174068 OpenAlex:https://openalex.org/W3013175876

NIH

Grant: 5P41GM103426-25

NATIONAL BIOMEDICAL COMPUTATION RESOURCE

NIGMS NIH HHS

Grant: P41 GM103426

FWCI

2.29

Citation Percentile

0.9%

Influential Citations

Citation Trend

2019

2020

2021

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://jitc.bmj.com/content/jitc/8/1/e000613.full.pdf

GOLDhttps://jitc.bmj.com/content/jitc/8/1/e000613.full.pdf

publisherhttps://jitc.bmj.com/content/jitc/8/1/e000613.full.pdf

publisherhttps://syndication.highwire.org/content/doi/10.1136/jitc-2020-000613

journalhttps://doi.org/10.1136/jitc-2020-000613

Fields of Study

Cancer Immunotherapy and BiomarkersCancer Genomics and DiagnosticsFerroptosis and cancer prognosisMedicineBiology0301 basic medicine03 medical and health sciences0302 clinical medicineAntineoplastic Agents, ImmunologicalBiomarkers, TumorDNA Mutational AnalysisGene Expression Regulation, NeoplasticGenome, HumanHigh-Throughput Nucleotide SequencingHumansMutationNeoplasmsPrognosisSurvival RateTumor Burden

MeSH Terms

Antineoplastic Agents, ImmunologicalDNA Mutational AnalysisHumansMutationNeoplasmsPrognosisBiomarkers, TumorGenome, HumanGene Expression Regulation, NeoplasticSurvival RateTumor BurdenHigh-Throughput Nucleotide Sequencing

Keywords

ConcordanceIndelExomeExome sequencingComputational biologyGeneMedicineWhole genome sequencingOncologyGeneticsGenomeMutationBiologySingle-nucleotide polymorphismGenotypeImmunotherapyGenetic markersTranslational Medical ResearchTumor BiomarkersDNA Mutational Analysis610Antineoplastic Agents576Antineoplastic Agents, ImmunologicalNeoplasmsBiomarkers, TumorHumansRC254-282Clinical/Translational Cancer ImmunotherapyNeoplasticTumorGenome, HumanNeoplasms. Tumors. Oncology. Including cancer and carcinogensHigh-Throughput Nucleotide SequencingPrognosisTumor BurdenGene Expression Regulation, NeoplasticSurvival RateImmunologicalGene Expression RegulationBiomarkersHuman

Sustainable Development Goals

SDG 3: 3. Good healthSDG 10: 10. No inequality

Additional file 1 of Tumor mutation burden estimated by a 69-gene-panel is associated with overall survival in patients with diffuse large B-cell lymphoma

10.6084/m9.figshare.14220695.v1figshare

Additional file 1 of Tumor mutation burden estimated by a 69-gene-panel is associated with overall survival in patients with diffuse large B-cell lymphoma

10.6084/m9.figshare.14220695figshare

Additional file 8 of Tumor mutation burden estimated by a 69-gene-panel is associated with overall survival in patients with diffuse large B-cell lymphoma

10.6084/m9.figshare.14220716.v1figshare

Additional file 8 of Tumor mutation burden estimated by a 69-gene-panel is associated with overall survival in patients with diffuse large B-cell lymphoma

10.6084/m9.figshare.14220716figshare

Additional file 2 of Tumor mutation burden estimated by a 69-gene-panel is associated with overall survival in patients with diffuse large B-cell lymphoma

10.6084/m9.figshare.14220698.v1figshare

Additional file 3 of Tumor mutation burden estimated by a 69-gene-panel is associated with overall survival in patients with diffuse large B-cell lymphoma

10.6084/m9.figshare.14220701.v1figshare

Additional file 5 of Tumor mutation burden estimated by a 69-gene-panel is associated with overall survival in patients with diffuse large B-cell lymphoma

10.6084/m9.figshare.14220707figshare

Additional file 3 of Tumor mutation burden estimated by a 69-gene-panel is associated with overall survival in patients with diffuse large B-cell lymphoma

10.6084/m9.figshare.14220701figshare

Additional file 6 of Tumor mutation burden estimated by a 69-gene-panel is associated with overall survival in patients with diffuse large B-cell lymphoma

10.6084/m9.figshare.14220710.v1figshare

Additional file 7 of Tumor mutation burden estimated by a 69-gene-panel is associated with overall survival in patients with diffuse large B-cell lymphoma

10.6084/m9.figshare.14220713figshare

Additional file 6 of Tumor mutation burden estimated by a 69-gene-panel is associated with overall survival in patients with diffuse large B-cell lymphoma

10.6084/m9.figshare.14220710figshare

Additional file 4 of Tumor mutation burden estimated by a 69-gene-panel is associated with overall survival in patients with diffuse large B-cell lymphoma

10.6084/m9.figshare.14220704figshare

Additional file 2 of Tumor mutation burden estimated by a 69-gene-panel is associated with overall survival in patients with diffuse large B-cell lymphoma

10.6084/m9.figshare.14220698figshare

Additional file 5 of Tumor mutation burden estimated by a 69-gene-panel is associated with overall survival in patients with diffuse large B-cell lymphoma

10.6084/m9.figshare.14220707.v1figshare

Additional file 7 of Tumor mutation burden estimated by a 69-gene-panel is associated with overall survival in patients with diffuse large B-cell lymphoma

10.6084/m9.figshare.14220713.v1figshare

Additional file 4 of Tumor mutation burden estimated by a 69-gene-panel is associated with overall survival in patients with diffuse large B-cell lymphoma

10.6084/m9.figshare.14220704.v1figshare